Selected research
Industry Research
Daratumumab Industry Research Report 2026
Market perspective
The global Daratumumab market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Daratumumab is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Daratumumab is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Daratumumab is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Daratumumab include Johnson＆Johnson. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Daratumumab market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Daratumumab Market by Company
Johnson＆Johnson
Daratumumab Segment by Type
100mg Injection
400mg Injection
Daratumumab Segment by Application
Multiple Myeloma
Follicular Lymphoma
Diffuse Large B Cell Lymphoma
Mantle Cell Lymphoma
Others
Daratumumab Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Daratumumab market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Daratumumab and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Daratumumab.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Daratumumab manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Daratumumab by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Daratumumab in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 100mg Injection
- 400mg Injection
Applications
- Multiple Myeloma
- Follicular Lymphoma
- Diffuse Large B Cell Lymphoma
- Mantle Cell Lymphoma
- Others
Companies covered
- Johnson＆Johnson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Daratumumab Market Size (2021-2032)
- 2.2.2 Global Daratumumab Sales (2021-2032)
- 2.2.3 Global Daratumumab Market Average Price (2021-2032)
- 2.3 Daratumumab by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 100mg Injection
- 2.3.3 400mg Injection
- 2.4 Daratumumab by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Multiple Myeloma
- 2.4.3 Follicular Lymphoma
- 2.4.4 Diffuse Large B Cell Lymphoma
- 2.4.5 Mantle Cell Lymphoma
- 2.4.6 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Daratumumab Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Daratumumab Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Daratumumab Revenue of Manufacturers (2021-2026)
- 3.4 Global Daratumumab Average Price by Manufacturers (2021-2026)
- 3.5 Global Daratumumab Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Daratumumab, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Daratumumab, Product Type & Application
- 3.8 Global Manufacturers of Daratumumab, Established Date
- 3.9 Global Daratumumab Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Johnson＆Johnson
- 4.1.1 Johnson＆Johnson Company Information
- 4.1.2 Johnson＆Johnson Business Overview
- 4.1.3 Johnson＆Johnson Daratumumab Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Johnson＆Johnson Daratumumab Product Portfolio
- 4.1.5 Johnson＆Johnson Recent Developments
5 Global Daratumumab Market Scenario by Region
- 5.1 Global Daratumumab Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Daratumumab Sales by Region: 2021-2032
- 5.2.1 Global Daratumumab Sales by Region: 2021-2026
- 5.2.2 Global Daratumumab Sales by Region: 2027-2032
- 5.3 Global Daratumumab Revenue by Region: 2021-2032
- 5.3.1 Global Daratumumab Revenue by Region: 2021-2026
- 5.3.2 Global Daratumumab Revenue by Region: 2027-2032
- 5.4 North America Daratumumab Market Facts & Figures by Country
- 5.4.1 North America Daratumumab Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Daratumumab Sales by Country (2021-2032)
- 5.4.3 North America Daratumumab Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Daratumumab Market Facts & Figures by Country
- 5.5.1 Europe Daratumumab Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Daratumumab Sales by Country (2021-2032)
- 5.5.3 Europe Daratumumab Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Daratumumab Market Facts & Figures by Country
- 5.6.1 Asia Pacific Daratumumab Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Daratumumab Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Daratumumab Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Daratumumab Market Facts & Figures by Country
- 5.7.1 South America Daratumumab Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Daratumumab Sales by Country (2021-2032)
- 5.7.3 South America Daratumumab Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Daratumumab Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Daratumumab Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Daratumumab Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Daratumumab Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Daratumumab Sales by Type (2021-2032)
- 6.1.1 Global Daratumumab Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Daratumumab Sales Market Share by Type (2021-2032)
- 6.2 Global Daratumumab Revenue by Type (2021-2032)
- 6.2.1 Global Daratumumab Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Daratumumab Revenue Market Share by Type (2021-2032)
- 6.3 Global Daratumumab Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Daratumumab Sales by Application (2021-2032)
- 7.1.1 Global Daratumumab Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Daratumumab Sales Market Share by Application (2021-2032)
- 7.2 Global Daratumumab Revenue by Application (2021-2032)
- 7.2.1 Global Daratumumab Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Daratumumab Revenue Market Share by Application (2021-2032)
- 7.3 Global Daratumumab Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Daratumumab Value Chain Analysis
- 8.1.1 Daratumumab Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Daratumumab Production Mode & Process
- 8.2 Daratumumab Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Daratumumab Distributors
- 8.2.3 Daratumumab Customers
9 Global Daratumumab Analyzing Market Dynamics
- 9.1 Daratumumab Industry Trends
- 9.2 Daratumumab Industry Drivers
- 9.3 Daratumumab Industry Opportunities and Challenges
- 9.4 Daratumumab Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst